CL2004000754A1 - Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central. - Google Patents

Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.

Info

Publication number
CL2004000754A1
CL2004000754A1 CL200400754A CL2004000754A CL2004000754A1 CL 2004000754 A1 CL2004000754 A1 CL 2004000754A1 CL 200400754 A CL200400754 A CL 200400754A CL 2004000754 A CL2004000754 A CL 2004000754A CL 2004000754 A1 CL2004000754 A1 CL 2004000754A1
Authority
CL
Chile
Prior art keywords
imidazol
piperidine
phenyl
prepare
prevent
Prior art date
Application number
CL200400754A
Other languages
English (en)
Inventor
Thomas H W Janssens F Steckler
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2004000754A1 publication Critical patent/CL2004000754A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL200400754A 2003-04-11 2004-04-07 Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central. CL2004000754A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP0303879 2003-04-11

Publications (1)

Publication Number Publication Date
CL2004000754A1 true CL2004000754A1 (es) 2005-02-25

Family

ID=33154992

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400754A CL2004000754A1 (es) 2003-04-11 2004-04-07 Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.

Country Status (12)

Country Link
US (1) US20060287345A1 (es)
EP (1) EP1615644B1 (es)
JP (1) JP2006522775A (es)
AR (1) AR044010A1 (es)
AT (1) ATE353649T1 (es)
AU (1) AU2004228960A1 (es)
CA (1) CA2521186A1 (es)
CL (1) CL2004000754A1 (es)
DE (1) DE602004004771T2 (es)
ES (1) ES2282858T3 (es)
TW (1) TW200509913A (es)
WO (1) WO2004089372A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1390848B1 (it) 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
EP2149370A1 (en) 2008-07-31 2010-02-03 Neuroscienze Pharmaness S.C. A R.L. Diazabicyclic compounds and microemulsions thereof
JP2011030565A (ja) * 2009-07-06 2011-02-17 Yokohama City Univ 社会的隔離モデル動物
IT1396951B1 (it) 2009-12-18 2012-12-20 Neuroscienze Pharmaness S C A R L Composti farmaceutici
ES2770978T3 (es) * 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
RU2762567C2 (ru) 2015-03-17 2021-12-21 Ниппон Кемифар Ко., Лтд. Производное морфинана
JPWO2018030382A1 (ja) 2016-08-09 2019-06-13 日本ケミファ株式会社 モルヒナン誘導体
JP6840155B6 (ja) 2016-09-16 2025-06-17 日本ケミファ株式会社 モルヒナン誘導体のオピオイドδ受容体アゴニスト関連疾患の治療のための使用
JOP20200272A1 (ar) 2018-05-01 2020-11-01 Merck Sharp & Dohme مُعدّلات تفارغية سبيروبيريدين لمستقبلات أستيل كولين نيكوتينية
AU2020385852A1 (en) 2019-11-22 2022-06-02 Nippon Chemiphar Co., Ltd. Pyrazolomorphinan derivative
WO2022181763A1 (ja) 2021-02-26 2022-09-01 学校法人東京理科大学 ストレス関連障害の治療又は予防用医薬組成物
JP2024511169A (ja) * 2021-03-26 2024-03-12 ピーエックス・アイエヌジー，エルエルシー 運動誘発性精神疲労を低減するためのパラキサンチンの使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354863A (en) * 1992-01-21 1994-10-11 G. D. Searle & Co. Opioid agonist compounds
DE19805370A1 (de) * 1997-03-14 1998-09-17 Gruenenthal Gmbh Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen
HN1999000149A (es) * 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
EP1038872A1 (en) * 1999-02-22 2000-09-27 Pfizer Products Inc. 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
DE19939044A1 (de) * 1999-08-18 2001-03-15 Gruenenthal Gmbh Verwendung von Morphinanderivaten als Arzneimittel
SE0101767D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
CA2462374C (en) * 2001-10-15 2011-01-18 Janssen Pharmaceutica N.V. Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
JP4417108B2 (ja) * 2001-10-15 2010-02-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新規な置換された４−フェニル−４−［１ｈ−イミダゾール−２−イル］−ピペリジン誘導体および選択的非ペプチドデルタオピオイドアゴニストとしてのそれらの使用

Also Published As

Publication number Publication date
DE602004004771D1 (de) 2007-03-29
EP1615644B1 (en) 2007-02-14
ATE353649T1 (de) 2007-03-15
AR044010A1 (es) 2005-08-24
WO2004089372A1 (en) 2004-10-21
US20060287345A1 (en) 2006-12-21
EP1615644A1 (en) 2006-01-18
JP2006522775A (ja) 2006-10-05
ES2282858T3 (es) 2007-10-16
CA2521186A1 (en) 2004-10-21
DE602004004771T2 (de) 2007-12-06
TW200509913A (en) 2005-03-16
AU2004228960A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
CL2004000695A1 (es) Compuestos derivados de 4-fenil piperidina, composicion farmaceutica, util como modulador del receptor opioides, para tratar sindrome de intestino irritable, adiccion o dependencia de drogas, depresion, ansiedad, esquizofrenia, trastornos de la alime
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
SG170813A1 (en) New compounds
CL2011000478A1 (es) Compuestos derivados de 2-imidazol-propanamida sustituidos, activadores de glucoquinasa; composicion farmaceutica, util para tratar o retrasar la progresion o aparacion de la diabetes tipo ii o trastornos relacionados con la diabetes.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2004000526A1 (es) Compuestos derivados de dibenzofurano, carbazoles, inhibidores de fosfodiesterasa tipo 4; procedimiento de preparacion; y su uso en el tratamiento de trastornos y condiciones inflamatorias, del sistema nervioso central y diabetes insulino resistente.
CU23780B7 (es) Compuestos de quinolina heteroaromaticos y su uso como inhibidores de pde10
CR9135A (es) Derivados novedosos pirrolidilo de compuestos heteroaromaticos
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
DE502006006854D1 (de) Substituierte benzo (d) isoaxol-3-yl-amin-verbindungen als analgetika
GB0510141D0 (en) Novel compounds B3
TW200732296A (en) Novel compounds
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
CY1115789T1 (el) 2,3-διυδροβενζο[1,4]διοξιν-2-υλομεθυλο παραγωγα ως αλφα2c ανταγωνιστες για χρηση στη θεραπευτικη αγωγη παθησεων του περιφερικου και του κεντρικου νευρικου συστηματος
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
DE602005017753D1 (de) Mittel für die transdermale verabreichung von nikotin
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
JO2769B1 (en) Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
NO20091052L (no) Diaryleterderivater og anvendelser derav
UA97826C2 (ru) Быстро диссоциирующие антагонисты рецептора 2 дофамина
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.